Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013055865) MICRORNAS IN NEURODEGENERATIVE DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/055865 International Application No.: PCT/US2012/059671
Publication Date: 18.04.2013 International Filing Date: 11.10.2012
IPC:
C12N 15/113 (2010.01) ,C12Q 1/68 (2006.01) ,A61P 25/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. [US/US]; 75 Francis Street Boston, Massachusetts 02115, US
Inventors:
WEINER, Howard; US
BUTOVSKY, Oleg; US
Agent:
REITER, Tiffany; Fish & Richardson P.C. P.O. Box 1022 Minneapolis, Minnesota 55440-1022, US
Priority Data:
61/545,96811.10.2011US
61/601,20521.02.2012US
Title (EN) MICRORNAS IN NEURODEGENERATIVE DISORDERS
(FR) MICROARN DANS DES MALADIES NEURODÉGÉNÉRATIVES
Abstract:
(EN) The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the rate of disease progression in a subject having a neurodegenerative disorder, selecting a subject for treatment of a neurodegenerative disorder, selecting a subject for participation in a clinical study, and determining the efficacy of treatment of a neurodegenerative disorder. These methods include determining the level of one or more microRNAs and/or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16- or CD14+CD16- monocyte) or in cerebrospinal fluid (CSF) from the subject and comparing the level of the one or more microRNAs and/or the level of the one or more inflammatory markers with a reference level(s). Also provided are methods of treating a neurodegenerative disorder that include administering to a subject at least one agent that decreases or increases the level or activity of one or more microRNAs or one or more inflammatory markers in a monocyte (e.g., a CD14+CD16- or CD14+CD16- monocyte) or in the CSF of a subject.
(FR) L'invention concerne des méthodes de diagnostic de maladies neurodégénératives (par exemple la sclérose latérale amyotrophique et la sclérose en plaques) chez un sujet, par l'identification de sujets présentant un risque de développer un maladie neurodégénérative, la prédiction de la vitesse de la progression de la maladie chez un sujet présentant un maladie neurodégénérative, la sélection d'un sujet pour le traitement d'un maladie neurodégénérative, la sélection d'un sujet pour la participation dans une étude clinique, et la détermination de l'efficacité du traitement d'un maladie neurodégénérative. Ces procédés comprennent la détermination du niveau d'au moins un microARN et/ou d'au moins un marqueur inflammatoire dans un monocyte (par exemple CD14+CD16- ou un monocyte CD14+CD16-) ou dans le liquide céphalorachidien (CSF) provenant du sujet et la comparaison du niveau d'au moins un microARN et/ou du niveau d'au moins un marqueur inflammatoire avec un ou des niveaux de référence. L'invention concerne également des méthodes de traitement d'un maladie neurodégénérative qui comprend l'administration à un sujet d'au moins un agent qui diminue au augmente le niveau ou l'activité d'au moins un microARN ou d'au moins un marqueur inflammatoire dans un monocyte (par exemple CD14+CD16- ou un monocyte CD14+CD16-) ou dans le CSF d'un sujet.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)